Nilotinib Zentiva (Nilotinib)

Nilotinib works by selectively inhibiting the BCR‑ABL tyrosine kinase as well as related kinases such as c‑KIT and PDGFR. This blockade interferes with signaling pathways that promote uncontrolled cell division, leading to reduced proliferation of leukemic cells and increased programmed cell death.

The specific dose of Nilotinib Zentiva is determined by the prescribing clinician based on the patient’s disease phase, prior therapy, and individual health factors. Healthcare professionals adjust the regimen according to approved guidelines and patient response.

Safety data for nilotinib in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and breastfeeding is not recommended while on therapy. Physicians should discuss alternatives and risk mitigation with patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nilotinib belongs to the second‑generation tyrosine kinase inhibitor class and offers higher potency against BCR‑ABL compared with first‑generation agents like imatinib. It may achieve faster and deeper molecular responses, but its safety profile includes a higher risk of QT prolongation, requiring cardiac monitoring.

Nilotinib tablets should be stored at room temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

The medication is taken orally, usually once daily on an empty stomach (at least one hour before or two hours after a meal). Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their healthcare provider.

The most serious risks include QT‑interval prolongation, which can lead to life‑threatening arrhythmias, severe liver injury, pancreatitis, and marked reductions in blood cell counts (neutropenia, thrombocytopenia). Prompt reporting of symptoms such as palpitations, jaundice, severe abdominal pain, or unusual bleeding is essential.

Patients with a known hypersensitivity to nilotinib or any of its excipients should avoid the drug. Those with uncontrolled cardiac disease, significant QT prolongation, severe hepatic impairment, or who are taking contraindicated strong CYP3A4 inhibitors should not be treated with nilotinib without specialist evaluation.